Purpose. The pharmacology, pharmacokinetics, clinical efficacy, and safety of febuxostat are reviewed. Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the ...

Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline data of a ...

Notably, no adverse side effects were reported, in contrast to conventional gout remedies such as allopurinol or febuxostat—which may cause kidney and liver injuries and other reactions.

Crawling into bed to rest her painful left toe, Mel Gardener winced as she covered herself with a cotton sheet. Even the touch of this light fabric was excruciating.

It is estimated that up to 20% of US gout patients on standard-of-care allopurinol or febuxostat are physiologically refractory to these treatments. 2,3 About Shanton's Phase 2b Gout Study Shanton ...

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., March 28, 2025 /PRNewswire/ -- Shanton Pharma ...

It is estimated that up to 20% of US gout patients on standard-of-care allopurinol or febuxostat are physiologically refractory to these treatments. 2,3 Shanton's Phase 2b study is a six-month, ...